Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lorente, Leonardo ^a   Martín, María M ^b   Solé Vioĺn, Jordi ^c   Blanquer, José ^d   Labarta, Lorenzo ^e   Díaz, César ^f   Borreguero León, Juan M ^a   Orbe, Josune ^g   Rodríguez, José A ^g   Jiménez, Alejandro ^a   Páramo, José A ^g  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL SAN JORGE   (Spain)

^f HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 10; LACTIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; MMP9 PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; THROMBOCYTE COUNT; BLOOD; ENZYMOLOGY; EPIDEMIOLOGY; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; SPAIN; STATISTICAL MODEL; SURVIVOR;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-10; INTERNATIONAL NORMALIZED RATIO; LACTIC ACID; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROC CURVE; SEPSIS; SPAIN; SURVIVORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899627812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094318     Document Type: Article

References (39)

1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344-353. (Pubitemid 43145611)
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310. (Pubitemid 32641789)
3. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214.
4. Cauwe B, Opdenakker G (2010) Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45:351-423.
5. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, et al. (2002) Intracellular action of matrix-metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549.
6. Schulz R (2007) Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47: 211-242.
7. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516. (Pubitemid 33096184)
8. Sariahmetoglu M, Crawford BD, Leon H, Sawicka J, Li L, et al. (2007) Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 21: 2486-2495. (Pubitemid 47230678)
9. Elkington PT, O'Kane CM, Friedland JS (2005) The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 142: 12-20. (Pubitemid 41361000)
10. Lijnen H (2002) Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 67: 92-98.
11. Santos-Mart?́nez MJ, Medina C, Jurasz P, Radomski MW (2008) Role of metalloproteinases in platelet function. Thromb Res 121: 535-542. (Pubitemid 351174273)
12. de Lizarrondo SM, Roncal C, Calvayrac O, Rodr?́guez C, Varo N, et al. (2012) Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol 32: 1477-1487.
13. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas H, et al. (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 20: 458-464. (Pubitemid 129504868)
14. Yassen KA, Galley HF, Webster NR (2001) Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 56: 729-732. (Pubitemid 32755137)
15. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, et al. (2006) Matrixmetalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect 38: 867-872. (Pubitemid 44489515)
16. Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H (1998) Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 316: 355-360. (Pubitemid 29019588)
17. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, et al. (1996) Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 346-352. (Pubitemid 26269102)
18. Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, et al. (2003) Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 167: 593-598.
19. Lorente L, Martin MM, Labarta L, Diaz C, Sole-Violan J, et al. (2009) Matrix metalloproteinase-9,-10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 13: R158.
20. Lauhio A, Hä stbacka J, Pettilä V, Tervahartiala T, Karlsson S, et al. (2011) Serum MMP-8,-9 and TIMP-1 in sepsis: High serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 64: 590-594.
21. Yazdan-Ashoori P, Liaw P, Toltl L, Webb B, Kilmer G, et al. (2011) Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. J Crit Care 26: 556-565.
22. Gäddnä s FP, Sutinen MM, Koskela M, Tervahartiala T, Sorsa T, et al. (2010) Matrix-metalloproteinase-2,-8 and-9 in serum and skin blister fluid in patients with severe sepsis. Crit Care 14: R49.
23. Lorente L, Mart?́n MM, Plasencia F, Solé-Violán J, Blanquer J, et al. (2013) The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Crit Care 17: R94.
24. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et alInternational Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference (2003) Intensive Care Med 29:530-538. (Pubitemid 36523666)
25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, et al. (1996) The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med 22: 707-710. (Pubitemid 26254283)
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829. (Pubitemid 15250137)
27. Sheu JR, Fong TH, Liu CM, Shen MY, Chen TL, et al. (2004) Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol 143: 193-201. (Pubitemid 39280039)
28. Lee YM, Lee JJ, Shen MY, Hsiao G, Sheu JR (2006) Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation. Eur J Pharmacol 537: 52-58.
29. Aznaouridis K, Vlachopoulos C, Dima I, Vasiliadou C, Ioakeimidis N, et al. (2007) Divergent associations of tissue inhibitors of metalloproteinases-1 and-2 with the prothrombotic/fibrinolytic state. Atherosclerosis 195: 212-215. (Pubitemid 47561951)
30. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, et al. (2006) Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151: 1101.e1-8.
31. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, et al. (2006) Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 84: 398-405. (Pubitemid 46052628)
32. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, et al. (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354: 556-560. (Pubitemid 29381370)
33. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, et al. (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 61: 459-462. (Pubitemid 19168155)
34. Zhu S, Ashok M, Li J, Li W, Yang H, et al. (2009) Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 15: 275-282.
35. Ho CH, Hsu SP, Yang CC, Lee YH, Chien CT (2009) Sialic acid reduces acute endotoxemia-induced liver dysfunction in the rat. Shock 32: 228-235.
36. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, et al. (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13: 2054-2060.
37. Jung K, Lein M, Laube C, Lichtinghagen R (2001) Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314: 241-244. (Pubitemid 33079205)
38. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386: 616-619. (Pubitemid 27175428)
39. Radomski A, Jurasz P, Sanders EJ, Overall CM, Bigg HF, et al. (2002) Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 137: 1330-1338. (Pubitemid 36071751)